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Bacteria gain antibiotic resistance genes by horizontal acquisition of 12 
mobile genetic elements (MGE) from other lineages. Newly acquired 13 
MGEs are often poorly adapted causing intragenomic conflicts, resolved 14 
by compensatory adaptation of the chromosome, the MGE or reciprocal 15 
coadaptation. The footprints of such intragenomic coevolution are 16 
present in bacterial genomes, suggesting an important role promoting 17 
genomic integration of horizontally acquired genes, but direct 18 
experimental evidence of the process is limited. Here we show adaptive 19 
modulation of tetracycline resistance via intragenomic coevolution 20 
between Escherichia coli and the multi-drug resistant (MDR) plasmid 21 
RK2. Tetracycline treatments, including monotherapy or combination 22 
therapies with ampicillin, favoured de novo chromosomal resistance 23 
mutations coupled with mutations on RK2 impairing the plasmid-24 
encoded tetracycline efflux-pump. These mutations together provided 25 
increased tetracycline resistance at reduced cost. Additionally, the 26 
chromosomal resistance mutations conferred cross-resistance to 27 
chloramphenicol. Reciprocal coadaptation was not observed under 28 
ampicillin-only or no antibiotic selection. Intragenomic coevolution can 29 
create genomes comprised of multiple replicons that together provide 30 
high-level, low-cost resistance, but the resulting co-dependence may 31 
limit the spread of coadapted MGEs to other lineages.   32 
 33 
  34 
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Horizontal gene transfer (HGT) is a fundamental process in bacterial evolution 35 
that accelerates adaptation by sharing ecologically important accessory traits 36 
between lineages1. These accessory traits are themselves frequently located 37 
on semi-autonomous mobile genetic elements (MGE), such as conjugative 38 
plasmids, that encode genes for their own replication, partition and horizontal 39 
transfer2,3. Conjugative multidrug resistance (MDR) plasmids, encoding 40 
antibiotic resistance genes (ARG) against multiple classes of antibiotics, are 41 
of particular clinical concern since they allow instantaneous acquisition of 42 
MDR phenotypes and thus potentiate the rapid emergence of MDR bacterial 43 
pathogens4,5. Newly acquired conjugative plasmids are often costly since the 44 
plasmid is unlikely to be well adapted to the new genetic background, causing 45 
intragenomic conflict6. The cost of plasmid carriage is likely to arise due to the 46 
metabolic burden of maintaining, transcribing and translating plasmid genes7, 47 
as well as via disruption of cellular homeostasis caused by gene regulatory 48 
interference between chromosomal and plasmid regulators8,9, and cytotoxic 49 
effects of plasmid gene products6.  50 
 51 
An important route to resolving this intragenomic conflict is compensatory 52 
evolution to ameliorate the cost of plasmid acquisition10. Experimental 53 
evolution suggests that compensatory evolution can arise via mutations 54 
located on either the chromosome or the plasmid, or via intragenomic 55 
coevolution involving both plasmid and chromosome mutations8,9,11,12. 56 
Comparative genomics suggests a key role for compensatory evolution in 57 
natural bacterial populations, potentially stabilising MDR plasmids within 58 
lineages and thus allowing the evolutionary emergence by HGT of MDR 59 
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pathogens13. A key outstanding question is how the mode of compensatory 60 
evolution following MDR plasmid acquisition varies with antibiotic treatment. 61 
Here we experimentally evolved Escherichia coli MG1655 carrying the MDR 62 
plasmid RK2 (encoding tetracycline and ampicillin resistance genes) under a 63 
range of antibiotic treatment regimes including no antibiotic, mono- and 64 
combination-therapies of tetracycline and ampicillin. Following 530 65 
generations of selection we quantified evolved changes in antibiotic 66 
resistance and fitness, and used genome sequencing to determine the 67 
genetic bases of the observed adaptation.  68 
 69 
Results 70 
Thirty independent isogenic populations of E. coli MG1655 carrying the MDR 71 
plasmid RK214, which encodes resistances to tetracycline (TET) and ampicillin 72 
(AMP), were experimentally evolved for ~530 generations (80 days), under 73 
five antibiotic treatments (six independently evolving lines per treatment): no 74 
antibiotic (N), AMP (A), TET (T), AMP plus TET (AT), and 24 hour cycling 75 
between AMP and TET (A/T) (see methods). Plasmids remained at high 76 
frequency in all populations for the duration of the selection experiment. 77 
Plasmid-free segregants were only observed at very low frequency in two of 78 
the six populations from treatment N (Supplementary Fig. 1), whereas 79 
transposition of resistance genes from RK2 onto the host’s chromosome was 80 
never observed.  81 
 82 
To test for changes in antibiotic resistance profiles following evolution we first 83 
determined the minimum inhibitory concentration (MIC) of evolved lineages to 84 
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TET and AMP. The susceptibility of the evolved strains to antibiotics differed 85 
between treatments (Fig. 1a). We observed a four-fold increase in TET MIC in 86 
evolved strains from the T and AT treatments and a small increase in lineages 87 
that had evolved under the cycling A/T treatment compared with the ancestral 88 
MG1655 with ancestral RK2 (Anc-RK2), whereas evolved strains from 89 
treatments N and A showed no change in tetracycline MIC (ANOVA, F5,30 = 90 
6.103, p < 0.001; Post-hoc Tukey Tests, Anc-RK2:T p < 0.001, Anc-RK2:AT p 91 
< 0.01, Anc-RK2:N p = 0.525, Anc-RK2:A p = 0.783). By contrast, we 92 
observed no change in resistance to AMP in any treatment (ANOVA, F5,30 = 93 
1.212, p = 0.327), possibly due to a lower relative selection pressure imposed 94 
by the concentration of AMP used in the experiment compared to the 95 
concentration of TET15. Interestingly, TET selection led to the evolution of 96 
bacteria that were cross-resistant to chloramphenicol (CML), although the 97 
extent of the evolved cross-resistance varied between treatments (ANOVA, 98 
F5,30 = 24.25, p < 0.001); with CML MIC increasing 8-, 4-, and 2-fold in T, AT, 99 
A/T treatments, respectively. Consistent with CML cross-resistance being a 100 
correlated response to TET selection, evolved strains from both the N and A 101 
treatments remained equally sensitive to CML as the ancestral MG1655(RK2) 102 
(Post-hoc Tukey Tests, Anc-RK2:N p = 0.975, Anc-RK2:A p = 0.993). Thus 103 
whereas T and AT treatments, and to a lesser extent the cycling A/T 104 
treatment, led to the evolution increased TET resistance and cross-resistance 105 
to CML, evolved lineages from the N and A treatments showed no change in 106 
their resistance profile. 107 
 108 
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To examine the genetic bases of evolved changes in resistance we next 109 
obtained whole genome sequences for one randomly selected clone per 110 
population. Excluding hypermutators, evolved clones had acquired between 2 111 
and 11 mutations, located exclusively on the chromosome in non-TET 112 
treatments (C, N, A), and on both the chromosome and plasmid in the 113 
treatments including TET (T, AT, A/T) (Supplementary Fig. 2, Supplementary 114 
Table 1). Of all the observed mutations 13.2% were synonymous and 19% 115 
were intergenic, the remaining non-synonymous mutations (67.8%) comprised 116 
missense mutations (42.8%), frameshifts (10.6%), insertion sequences (5.6%) 117 
and gene deletions (5.4%), and these were analysed further. While the 118 
variance in the number of non-synonymous mutations did not differ between 119 
treatments (Analysis of multivariate homogeneity of group variances excluding 120 
hypermutators F5,26 = 1.8617, p = 0.1358), the loci affected by non-121 
synonymous mutations did vary between treatments (Permutational ANOVA, 122 
permutation test: F5,26 = 2.5231, p < 0.01, Bonferroni corrected). Clones that 123 
had evolved under TET selection (T, AT, A/T) had significantly different sets 124 
of non-synonymous mutations compared to evolved clones from the other 125 
treatments (C, N, A) (permutation test: F1,30 = 6.9463, p < 0.01, Bonferroni 126 
corrected), with a larger genetic distance between TET and non-TET 127 
treatments than within these treatment groups (Fig. 2a). Thus TET-selected 128 
lineages followed an evolutionary trajectory distinct from non-TET-selected 129 
lineages, leading to mutations on both the chromosome and the plasmid, 130 
which suggest that TET selection favoured bacteria-plasmid coadaptation. 131 
 132 
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Strikingly parallel mutations were observed between independent replicate 133 
populations both within and between TET-containing treatments (Fig. 2b). 134 
Highly parallel mutations are likely to represent adaptive evolution at these 135 
loci, and because mutations at these loci were not observed in the 136 
populations from the N and A treatments, these mutations were likely to be 137 
TET-specific adaptations. Mutations in the chromosomal genes ompF (16 out 138 
of 18 clones), and ychH (16 out of 18 clones) showed strong locus-level 139 
parallelism within all three TET-containing treatments. Mutations in ompF, 140 
encoding a major non-specific diffusion porin16, were all predicted loss-of-141 
function mutations, including the insertion of IS elements, frameshifts or 142 
premature stop codons. The loss of OmpF in E. coli reduces membrane 143 
permeability, including to antibiotics, and consequently is known to increase 144 
resistance to a wide spectrum of antibiotics17 including TET and CML18,19. 145 
Deletion of ompF (E. coli K-12 ∆ompF JW091220) significantly increased 146 
resistance to TET without the RK2 (t9.09 = 4.2836, p < 0.01), and further 147 
increased TET resistance when carrying RK2 (Two-way ANOVA Interaction 148 
F1,20 = 14.724, p < 0.01; Supplementary Fig. 4a). Parallel loss of function 149 
mutations (IS elements and frameshifts) in ychH were observed across all the 150 
TET treatments. YchH is a hypothetical stress-induced inner membrane 151 
protein21,22, but deletion of ychH (E. coli K-12 ∆ychH JW119620) did not 152 
significantly increase the resistance to TET with or without the plasmid 153 
(Supplementary Fig. 4b), suggesting that this general stress response may 154 
not be required under TET selection and is consequently selected against.  155 
 156 
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Mutations in several loci observed in the T and AT treatments were not 157 
present in the cycling A/T treatment. These included mutations in both acrR 158 
(10 out of 12 clones) and adhE (9 out of 12 clones). Mutations in adhE were 159 
extensively parallel at the nucleotide level, with 8 clones from independent 160 
populations all having the same missense SNP in the ethanol dehydrogenase 161 
domain23. The phenotypic significance of these mutations is unclear due to 162 
the multiple roles assigned to this protein, including multiple metabolic 163 
pathways24, but intriguingly the AdhE protein is known to exhibit binding 164 
activity to the 30S ribosome25, the primary TET target. The acrR gene 165 
encodes a repressor of AcrAB multidrug efflux pump26, the majority of 166 
mutations in acrR are predicted loss of function mutations, with IS elements 167 
and frameshifts observed in evolved strains. The deletion of acrR results in 168 
the overexpression of acrAB leading to MDR phenotypes27,28. Deletion of acrR 169 
(E. coli K-12 ∆acrR JW045320) alone did not significantly increase resistance 170 
to TET (t9.32 = -0.591, p = 0.339), but when combined with the RK2 plasmid 171 
did allow significantly increased growth in TET (t6.4 = 3.665, p < 0.01, 172 
Supplementary Fig. 4c). These findings are consistent with the higher TET 173 
resistance of evolved clones from the T and AT treatments versus the A/T 174 
treatment (Fig. 1a) and reflect overall weaker TET selection under the A/T 175 
cycling compared to the T and AT treatments where TET selection was 176 
constant. Interestingly, stronger TET selection appeared to constrain evolution 177 
at chromosomal loci not involved in resistance. For example, we observed 178 
highly parallel loss of function mutation in the flagellum operon in the A, N and 179 
A/T treatments, but only rarely observed mutations at these loci in T and AT 180 
treatments. Loss of the flagellar motility is a commonly observed adaptation of 181 
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E. coli to growth in liquid media29 and this may have been impeded by clonal 182 
interference or negative epistasis with chromosomal resistance mutations in 183 
populations under strong TET selection. Consistent with this, whereas 184 
evolved clones from the N and A treatments increased in fitness relative to the 185 
plasmid-free ancestor in antibiotic-free media, such fitness gains were not 186 
observed in evolved clones from the TET-containing treatments 187 
(Supplementary Fig. 5). 188 
 189 
To confirm that TET selection had led to the evolution of chromosomal 190 
resistance we next cured evolved strains of their plasmids and quantified 191 
resistance30. Evolved strains carrying putative chromosomal resistance 192 
mutations displayed increased TET (ANOVA, F5,30 = 42.63, p < 0.001), AMP 193 
(ANOVA, F5,30 = 12.55, p < 0.001) and CML (ANOVA, F5,30 = 35.88, p < 194 
0.001) resistance (Fig. 1b). Across all tested antibiotics, evolved clones 195 
carrying both ompF and acrR mutations had significantly increased resistance 196 
compared to the ancestral MG1655 (Post-hoc Tukey Tests, all p < 0.05), 197 
whereas cured evolved strains without either of these mutations (i.e. from the 198 
N and A treatments) did not (Post-hoc Tukey Tests, all p > 0.05). Interestingly, 199 
cured evolved clones from the cycling A/T treatment that carried only 200 
mutations in ompF but not in acrR showed marginally increased resistance to 201 
both TET and CML, but no detectable increase in AMP resistance, relative to 202 
MG1655. Thus TET selection favoured the de novo evolution of chromosomal 203 
resistance despite pre-existing plasmid-encoded TET resistance, and these 204 
chromosomal resistance mutations are responsible for the observed cross-205 
resistance to CML.  206 
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We observed parallel mutations on the plasmid exclusively in evolved clones 208 
from the TET-containing treatments (T, AT, and A/T). These mutations 209 
occurred in tetA/tetR (18 out of 18 clones; tetA: 13, tetR: 2, both: 3, Fig. 2b) 210 
which encode the tetracycline-specific efflux pump. The expression tetA is 211 
tightly regulated by the repressor tetR in the absence of tetracycline31,32. 212 
Mutations in tetA were dispersed throughout the gene, affecting the protein’s 213 
transmembrane, periplasmic and cytoplasmic domains33. Three of the five 214 
mutations observed in tetR are in direct contact with or in close proximity to 215 
the tetracycline binding pocket34, while the other two mutations are located in 216 
the central scaffolding of the protein, suggesting that they are likely to 217 
interfere with activity of the tetR repressor. Evolved plasmids carrying 218 
mutations in tetA or tetR displayed reduced resistance to TET in the ancestral 219 
MG1655 background compared to ancestral RK2 (Fig. 1d, ANOVA, F5,30 = 220 
4.586, p < 0.01). Consistent with reduced efficacy of plasmid-encoded 221 
resistance in evolved lineages with tetA/tetR mutations, when we replaced the 222 
evolved plasmid with ancestral RK2, this led to increased TET resistance 223 
(ANOVA, F5,30 = 71.86, p < 0.001, Anc-RK2:T,AT,A/T all p < 0.05).  224 
 225 
Our data suggest that evolved strains from TET-containing treatments 226 
adapted their resistance to TET by acquisition of weak chromosomal 227 
resistance mutations in combination with mutations that reduced the efficacy 228 
of the plasmid-encoded TET efflux pump. To understand the evolutionary 229 
benefits of this counterintuitive dual resistance strategy we first compared the 230 
effect of chromosomal background (evolved or ancestral) and plasmid 231 
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genotype (evolved or ancestral) on growth in the presence of 10 μg/ml TET 232 
(i.e., the concentration used in our selection experiment). The evolved 233 
chromosomal background carrying resistance mutations displayed a 234 
significantly shortened lag phase compared to the ancestral chromosomal 235 
background, irrespective of the plasmid genotype (Supplementary Fig. 6; 236 
ANOVA, F3,56 = 76.92, p < 0.001; Post-hoc Tukey Tests, Evolved 237 
Host:Ancestral Host all p < 0.001). This suggests that chromosomal 238 
resistances reducing membrane permeability to antibiotics allowed evolved 239 
strains to start growing faster in the presence of TET.  240 
 241 
Whereas evolved bacteria grew equally well with evolved or ancestral 242 
plasmids, ancestral bacteria displayed impaired growth with evolved 243 
compared to ancestral plasmids (Supplementary Fig. 6; Max OD, W = 93, p < 244 
0.01). This is consistent with the mutations in tetA/tetR reducing resistance 245 
but importantly confirms that this reduction is not evident when in combination 246 
with the chromosomal resistance mutations, which appear to compensate for 247 
the reduced efficacy of the plasmid-encoded efflux pump.  248 
 249 
We next competed evolved bacteria with either the evolved or ancestral 250 
plasmid against the ancestral MG1665(RK2) to compare the costs of carrying 251 
each plasmid genotype. The ancestral plasmid displayed a significantly higher 252 
cost than the evolved plasmid in the evolved chromosomal background 253 
(Supplementary Fig. 7, t25.71 = -2.287, p < 0.05). This suggests that the 254 
mutations to tetR/tetA ameliorate the cost of plasmid carriage but at the price 255 
of reduced efficacy of TET efflux. This is consistent with previous studies 256 
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showing a high cost of expressing the specific tetracycline efflux pump35. 257 
Taken together with the growth data, this suggests that although mutations to 258 
tetA/tetR reduce growth under tetracycline in the ancestral chromosomal 259 
background, they have minimal effect on resistance in the evolved 260 
chromosomal background due to the reduced membrane permeability and 261 
additional efflux systems expressed in the evolved chromosomal background 262 
carrying mutations in ompF and acrR, leading to high resistance and a 263 
lowered cost of plasmid carriage. This suggests that the chromosomal 264 
resistance mutations must have been gained prior to the mutations in the 265 
plasmid-encoded tetracycline efflux pump. To test this, for one population 266 
(AT2) we tracked the frequency over time of an observed IS-insertion in ompF 267 
by PCR and then determined by sequencing when these genotypes acquired 268 
mutations in the tetA/tetR genes. Consistent with the hypothesised order of 269 
mutations, the IS-insertion in ompF was first detected at transfer 8 and had 270 
swept to fixation by transfer 32, whereas mutations in tetA/tetR were not 271 




Our current model of bacterial evolution suggests that horizontal acquisition of 276 
ARGs accelerates resistance evolution by providing bacteria with ready-made 277 
resistance mechanisms, bypassing the requirement for rare de-novo 278 
mutations1. However, recent population genomic data suggesting that 279 
lineages independently acquire and then subsequently coevolve with MDR 280 
plasmids13,36,37 imply a more dynamic evolutionary process. Consistent with 281 
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this, here we show here that gaining an ARG can be just the starting point in 282 
the evolution of resistance and, due to the costs of expressing horizontally 283 
acquired ARGs, does not preclude subsequent de novo evolution of 284 
chromosomal resistance. Evolved strains from TET-containing treatments 285 
gained chromosomal resistance mutations reducing membrane permeability 286 
and enhancing efflux of TET and providing cross-resistance to other 287 
antibiotics, shortening lag phase in the presence of TET. These mutations 288 
also reduced the need for a fully operational plasmid-encoded tetracycline 289 
efflux pump, expression of which is highly costly35, allowing plasmid mutations 290 
in the TET efflux pump and its regulator which reduced the cost of plasmid-291 
encoded resistance. A consequence of this intragenomic coevolution is that 292 
the increased TET resistance of evolved strains from T, AT and A/T 293 
treatments required the action of both the chromosomal- and plasmid-294 
encoded resistances, which together acted multiplicatively. Thus intragenomic 295 
coevolution can lead to the evolution of bacterial genomes comprised of co-296 
dependent replicons, limiting the potential for onward transmission of the 297 
plasmid due to the weaker resistance it now encodes in other lineages.  298 
 299 
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Strains, culture conditions and evolution experiment 439 
E. coli MG1655 chromosomally labelled with GFP at the attB lambda 440 
attachment site was used in the evolution experiments. Isogenic E. coli 441 
MG1655-mCherry was used as a reference strain in competition and 442 
conjugation rate experiments. Both E. coli strains were provided by the Van 443 
Der Woude lab (University of York). The RK2 plasmid was introduced to the 444 
strains through conjugation from E. coli MV10 provided by the Thomas lab 445 
(University of Birmingham). All cultures were grown in Oxiod® Nutrient Broth 446 
(NB) at 37°C 5 ml in 50 ml microcosms shaken at 180 rpm. Independent 447 
selection lines were founded by 30 independent single colonies of E. coli 448 
MG1655-GFP harbouring RK2. These were grown overnight in non-selective 449 
conditions and split into the 5 antibiotic treatments, no antibiotic selection, 100 450 
μg/ml ampicillin, 10 μg/ml tetracycline, 100 μg/ml ampicillin plus 10 μg/ml 451 
tetracycline, and 24 hour cycling between 100 μg/ml ampicillin and 10 μg/ml 452 
tetracycline, with 6 replicate populations per treatment. In parallel, 6 453 
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independent E. coli MG1655-GFP colonies were picked for control treatments 454 
and grown under no selection. Selection lines were established by transferring 455 
50 μl of saturated overnight culture into 5ml of selective media. These 456 
populations were maintained through transfer of 1% of the population into 457 
fresh media and antibiotics every 24 hours for 80 transfers, resulting in ~6.64 458 
generations per day, totalling ~530 bacterial generations. For the cycling 459 
treatment 3 populations were initiated with 100μg/ml ampicillin and 3 460 
populations were initiated with 10μg/ml tetracycline. Culture density (OD600) 461 
was recorded every 24 hours. Plasmid prevalence was measure at the start 462 
and end of the selection experiment by screening 20 randomly picked 463 
colonies from each population using multiplex primers specific to RK2 464 
replication origin (Fw: ctcatctgtcaacgccgc, Rv: aaccggctatgtcgtgct), β-465 
lactamase (Fw: ataactacgatacgggagggc, Rv: acatttccgtgtcgccctta), and 466 
tetracycline efflux pump (Fw: tgggttctctatatcgggcg,Rv: tgggcgagtgaatgcagaat). 467 
These primers allowed for the detection of plasmid loss and transposition of 468 
resistances onto the chromosome. One end point clone was randomly 469 
selected from each population for phenotypic typing, curing, calculation of 470 
MICs and sequencing. Every eight transfers throughout the experiment 500 μl 471 
samples of whole populations were collected and stored in 25% glycerol at -472 
80°C. Whole populations were also plated out on non-selective media, 20 473 
individual clones were then randomly selected, sub-cultured for a further 24 474 
hours in non-selective media, and stored in 25% glycerol in 96 well plates. 475 
 476 
Relative Fitness  477 
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The relative fitness of the evolved plasmid bearing versus ancestral plasmid 478 
free strain was estimated by direct competition, with six replicate strains per-479 
treatment. The competitions were initiated with 50 μl of 1:1 mixtures of 480 
plasmid-bearing evolved strain and plasmid-bearing ancestral strain marked 481 
with mCherry from overnight cultures in 5ml of non-selective NB media. The 482 
relative fitness of the evolved strains was calculated by gaining exact viable 483 
cell counts at 0 hours and 24 hours, strains were distinguished through 484 
detection of fluorescent markers using Zeis Stereo Lumar v12 microscope. 485 
The relative fitness of plasmid-bearing bacteria was calculated as a ratio of 486 
Malthusian parameters38:  487 
= ln ,,ln ,,  
 488 
Fitness effects due to different markers was determined by competing plasmid 489 
free MG1655-GFP with plasmid free MG1655-mCherry, the relative fitness of 490 
MG1655-GFP was not significantly difference from 1 (t5=0.015584, p=0.9882) 491 
showing that there is no significant difference between the two marker strains. 492 
 493 
Relative fitness of evolved strains harbouring evolved plasmid or evolved 494 
strains harbouring ancestral plasmid versus ancestral plasmid bearing cells 495 
was estimated using the same method as above, with eighteen replicate 496 
strains per competition, but grown in 100 μl cultures in a 96 well plate, 37°C 497 
shaken at 600 rpm, 3 mm orbital radius, inoculated to an initial dilution of 498 
1:500. Again no fitness effect of markers was observed (t5=-0.2795, p=0.791). 499 
 500 
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Curing RK2 from evolved strains 501 
Evolved strains were cured using the pCURE curing system30. The anti-incP-1 502 
cassette (RK2 oriV, parD, korA, and incC genes) from pCURE11 was ligated 503 
into the pLAZ2 chloramphenicol resistant vector that contains the sacB gene 504 
allowing counter selection for plasmid free segregants. The resultant plasmid 505 
was transformed into chemically competent evolved strains and selected for 506 
using Cml 12.5 μg/ml. Single colony transformants were re-streaked on to 507 
Cml 12.5 μg/ml plates and Cml 12.5 μg/ml + 5% sucrose. Sucrose sensitive 508 
colonies were checked by PCR for the presence of the curing plasmid (Fw: 509 
aagttttggtgactgcgctc, Rv: caaagacgatgtggtagccg) and absence of RK2 β-510 
lactamase and tetA (primers as above). Successfully cured clones were 511 
cultured for 24 hours in non-selective media to allow segregation of the curing 512 
plasmid; sergeants were selected on antibiotic free, 5% sucrose plates. To 513 
confirm loss of both plasmids sucrose resistant colonies were check for 514 
sensitivity to chloramphenicol, ampicillin, and tetracycline, as well as PCR 515 
using primers mentioned above. Both the ancestral strain harbouring RK2 and 516 
ancestral plasmid free strains under went the curing process and were used 517 
as a comparison to cured evolved strains to control for curing process. 518 
Ancestral RK2 was introduced into the cured evolved strains, and evolved 519 
RK2 was introduced into the plasmid free ancestor though conjugation. Again, 520 
to control for the curing and conjugation steps, ancestral RK2 was conjugated 521 
into cured ancestral strains and used for comparison. Saturated overnight 522 
cultures of donor plasmid containing strains and recipient plasmid free strains 523 
were mixed 1:1, and 50 μl was used to inoculate 5ml NB. The mixed cultures 524 
were grown for 24 hours and plated out on to 100 μg/ml ampicillin to select for 525 
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transconjugants. Transconjugants were confirmed by fluoresces and PCR 526 
screening for RK2 plasmid.  527 
 528 
MIC 529 
To measure minimal inhibitory concentrations, six replicate cultures per-530 
treatment were grown overnight until stationary phase in 5 ml NB, the 531 
saturated cultures were then sub-cultured 50 μl into 5 ml fresh NB and grown 532 
to an OD600 of 0.5. These were then diluted into 96-well plates containing a 533 
log2 serial dilution of antibiotic (AMP, TET or CML) to an initial density of 534 
5×105 CFU/ml. 100 μl cultures were grown for 24 hours 37°C shaken at 600 535 
rpm, 3 mm orbital radius. OD600 was measured after 24 hours. 536 
 537 
Growth Curves 538 
Six replicate saturated overnight cultures per-treatment were sub-cultured to 539 
an OD600 of 0.5, and used to inoculate 100 μl NB supplemented with 10 μg/ml 540 
TET per well in 96-well plates at a final dilution of 1:1000. Plates were grown 541 
at 37°C with shaking at 300 rpm, 3 mm orbital radius for 24 hours, OD600 was 542 
measured every 16 minutes by Tecan infinite M200 Pro plate reader. Growth 543 
rates were calculated as the maximum slope of log2 transformed OD600 544 
covering four time points (~1 hour of growth), lag phase was calculated to end 545 
when growth rate reached 10% of the maximum achieved growth rate. 546 
 547 
Genome sequencing and analysis 548 
Whole genomes were extracted from each evolved population’s clone as well 549 
as the ancestral strain and ancestral strain harbouring the RK2 plasmid using 550 
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the DNeasy Blood and Tissue extraction kit (Qiagen). The total DNA was 551 
sequenced by MicrobesNG (http://www.microbesng.uk), which is supported 552 
by the BBSRC (grant number BB/L024209/1), using Illumnia MiSeq. Reads 553 
were mapped to E. coli MG1655 K-12 genome (GenBank accession 554 
U00096.3) and RK2 (GenBank accession BN000925.1) reference using BWA-555 
MEM39. Single nucleotide variants and small indel events were detected using 556 
GATK UnifiedGenotyper40 and SnpEff41, insertion sequences were identified 557 
using custom scripts and Integrative Genomics Viewer42, and large genome-558 
wide structural variants were detected using BreakDancer43. Mutations that 559 
were present in the ancestral clones were excluded, resulting in a set of 560 
mutations that were acquired during the selection experiment. 561 
 562 
Tracking mutations 563 
Populations that did not show a hypermutator phenotype, had insertion 564 
sequences within ompF, and mutations in the tetracycline resistance genes 565 
on the plasmid, from the constant TET treatments (T and AT treatments) were 566 
selected for further analysis to gain an understanding of the mutational 567 
timeline during the selection experiment. Insertion sequences within ompF 568 
were identified within whole populations of T4, AT2, AT3 and AT5 by PCR of 569 
the ompF gene (Fw: ACTTCAGACCAGTAGCCCAC, Rv: 570 
GCGCAATATTCTGGCAGTGA). A short product of 716 bp indicated no 571 
insertion sequence, a long product of 1484 bp indicted IS1 and a long product 572 
of 1911 bp indicted IS5. Whole population PCR indicated that ompF::IS 573 
mutants had swept into the population by transfer 40 for populations T4, AT2 574 
and AT5, and transfer 48 in population AT3. Frequency of ompF insertion 575 
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sequences were calculated by PCR of 20 clones from transfers 8, 16, 24, 32, 576 
and 40. Tetracycline resistance genes (tetA and tetR) from clones containing 577 
ompF::IS mutations from population AT2, transfers 8, 16, 24, and 32 were 578 
then Sanger sequenced to determine if ompF mutations arise before tetAR 579 
mutations (tetA: Fw: GGCTGCAACTTTGTCATG,Rv: 580 
TTCCAACCGCACTCCTAG, Internal1: ACAGCGCCTTTCCTTTG, Interal2: 581 
AAGGCAAGCAGGATGTAG; tetR: Fw: TCTGACGCGGTGGAAAG, Rv: 582 
ACGCGCGGATTCTTTATC, Internal1: GAGCCTGTTCAACGGTG, Internal2: 583 
TCTGACGACACGCAAAC). 584 
 585 
Statistical analysis 586 
To test if the mutations observed within each treatment had significantly 587 
different variances a multivariate homogeneity of groups variances test was 588 
conducted44. The binary presence or absence of a variant at each allele was 589 
use to calculate a Euclidean distance matrix between each population. This 590 
was used to test for homogeneity of variances between treatments using 591 
betadisper {vegan 2.4-0}. The variances between treatments were 592 
significantly different, with hypermutators significantly affecting within-group 593 
variation. These clones were removed from further analysis as significant 594 
differences in within-group variance can lead to falsely significant results 595 
when testing for differences between groups45. Permutational Multivariate 596 
Analysis of Variance was used to calculate whether different evolutionary 597 
treatments resulted in different sets of mutations45,46. Using the Euclidean 598 
distance matrix with hypermutators removed, the significance of within- and 599 
between-group distances was calculated using adonis2 {vegan 2.4-0}. The 600 
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data was partitioned into different groups, multiple testing was corrected for 601 
using Bonferroni correction. Neighbour Joining phylogeny was constructed 602 
using the binary presence or absence table with hypermutators removed. 603 
Tree estimation and bootstrap support was conducted using ape-package 604 
{ape 4.0}. Significant difference between two related samples was calculated 605 
using two sided, two-sample t-test. Shapiro-Wilk test was conducted to check 606 
for normality, when normality could not be assumed a non-parametric 607 
Wilcoxon signed-rank test was used. Differences among treatments growth 608 
under antibiotic selection were calculated by ANOVA of the integral of the 609 
resistance profiles, with subsequent Tukey multiple comparison of means. All 610 
statistical analysis was conducted in R (version 3.2.3). 611 
 612 
Data Availability 613 
The sequence data supporting the findings of this study are available at the 614 
European Nucleotide Archive, accession: PRJEB20735. All other data in this 615 
study is available at Figshare data depository 616 
(https://doi.org/10.6084/m9.figshare.5092225.v1). Custom code used to map 617 
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Figure 1 | Resistance profiles of evolved plasmids and hosts. Growth of 641 
a, evolved MG1655 strains with evolved RK2 plasmids b, evolved MG1655 642 
strains cured of evolved RK2 plasmids c, evolved MG1655 strains with 643 
ancestral RK2 plasmid and d, ancestral MG1655 clones with evolved RK2 644 
plasmids in the presence of tetracycline, ampicillin or chloramphenicol in 645 
comparison to ancestral MG1655. Points represent means of one clone from 646 
each of the six independent treatment populations, with SEM error bars. 647 
Dashed grey and black lines show the resistance profiles of plasmid free and 648 
plasmid containing ancestral strains respectively. Dashed lines in evolved 649 
host cured of plasmid plots (c) show ancestral MG1655 and ancestral 650 
 28 
MG1655(RK2) after curing process. Dashed lines in ancestral host evolved 651 
plasmid plots (d) show ancestral MG1655 and ancestral MG1655(RK2) which 652 
had under gone curing with ancestral RK2 subsequently reintroduced.  653 
Vertical dashed lines in AMP and TET resistance profiles show the 654 
concentrations of AMP (100 μg/ml) or TET (10 μg/ml) used in the selection 655 
experiment. 656 
 657 
Figure 2 | Mutations show treatment specific parallelism. a, An unrooted 658 
neighbour joining phylogeny of end-point evolved clones. The distance matrix 659 
was constructed from the binary presence or absence of variants at each 660 
gene relative to the ancestral strain; hypermutators were excluded from the 661 
analysis. Scale bar represents number of gene variants; percentage bootstrap 662 
support is shown at the branches, B=1000, values below 0.3 are omitted. Blue 663 
branches represent clone isolated from TET treatments. b, Mutations 664 
observed in evolved clones (excluding hypermutators) across treatment. 665 
Rings represent E. coli chromosomes or RK2 plasmids. Dots represent 666 
mutations, the size of the dots represent the number of mutations at the same 667 
loci across independent replicate populations. Plots of individual treatments 668 
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